Related references
Note: Only part of the references are listed.Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213
Hannah Woopen et al.
SUPPORTIVE CARE IN CANCER (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adherence to oral chemotherapy: Challenges and opportunities
Susan Krikorian et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
Luigi Celio et al.
BMC CANCER (2019)
ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients
Yasmeen Razvi et al.
SUPPORTIVE CARE IN CANCER (2019)
Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines
Erin McKenzie et al.
SUPPORTIVE CARE IN CANCER (2019)
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
L. Zhang et al.
ANNALS OF ONCOLOGY (2018)
NCCN Guidelines® Insights Antiemesis, Version 2.2017 Featured Updates to the NCCN Guidelines
Michael J. Berger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review
Ronald Chow et al.
SUPPORTIVE CARE IN CANCER (2016)
Nausea: a review of pathophysiology and therapeutics
Prashant Singh et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
R. de las Penas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Antiemetics: American Society of Clinical Oncology Focused Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Christina H. Ruhlmann et al.
LANCET ONCOLOGY (2016)
State Regulations and Opioid Use among Disabled Adults
Christopher M. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2016)
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K. Jordan et al.
ANNALS OF ONCOLOGY (2015)
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
Terry L. Ng et al.
ONCOLOGIST (2015)
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari
BIOMED RESEARCH INTERNATIONAL (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
R. J. Gralla et al.
ANNALS OF ONCOLOGY (2014)
Anticipatory nausea and vomiting due to chemotherapy
Charles Kamen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Anticipatory nausea and vomiting
Joseph A. Roscoe et al.
SUPPORTIVE CARE IN CANCER (2011)
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art
Steven M. Grunberg et al.
SUPPORTIVE CARE IN CANCER (2011)
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
Tobias Engel Ayer Botrel et al.
SUPPORTIVE CARE IN CANCER (2011)
Cochrane systematic reviews examine P6 acupuncture-point stimulation for nausea and vomiting
Jeanette Ezzo et al.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2006)
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
F Roila et al.
ANNALS OF ONCOLOGY (2006)
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting
J Ezzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
R Gralla et al.
ANNALS OF ONCOLOGY (2003)
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
PB Tremblay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial
A Molassiotis et al.
SUPPORTIVE CARE IN CANCER (2002)
How do we manage patients with refractory or breakthrough emesis?
MS Aapro
SUPPORTIVE CARE IN CANCER (2002)
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Focus on community respiratory virus infections
CA Dykewicz
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Share Paper
